en.Wedoany.com Reported - Bluejay Diagnostics announced the completion of a private placement, raising total gross proceeds of $8.5 million to support FDA approval-related matters and research and development activities. The offering sold 3,655,917 shares of common stock or pre-funded warrants to investors at a price of $2.325 per share, along with Series G warrants and short-term Series H warrants to purchase an equal number of common shares, each with an exercise price of $2.075 per share. The Series G warrants expire five years after the resale registration statement becomes effective, while the short-term Series H warrants expire within twenty-four months.

H.C. Wainwright & Co. served as the exclusive placement agent for this offering. The private placement was conducted pursuant to Section 4(a)(2) of the Securities Act of 1933 and Regulation D. The securities and the underlying common shares were not registered and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption.

If all Series G warrants and short-term Series H warrants are exercised for cash, the company could potentially receive approximately $15.2 million in additional proceeds, but there is no guarantee that the warrants will be exercised or generate cash proceeds. Net proceeds will be used for clinical studies related to FDA approval, other research and development activities, and general working capital needs.

Bluejay Diagnostics specializes in near-patient testing for critically ill patients. Its Symphony system is used for sepsis triage and disease progression monitoring, with the first candidate product, the IL-6 test, delivering results in approximately 20 minutes.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com